Company News

Business Recorder reported that a drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study said.

Business Recorder reported that a drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study said.

A quoted in the market news:

German researchers found that the GlaxoSmithKlein drug pazopanib (Votrient) extended the median time to disease worsening to 17.9 months compared with 12.3 months for patients given a placebo in a phase III clinical trial.

“Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments,” said lead author Andreas du Bois, a professor of gynaecologic oncology at Kliniken Essen Mitte in Germany.

The drug

Click here for the full news report by Business Recorder

MARKETS

Markets
TSX19660.31+114.40
TSXV602.38+8.85
DOW33160.83+333.83
S&P 5003828.110.00
NASD10616.200.00
ASX6958.90+25.20

COMMODITIES

Commodities
Gold1709.49-2.00
Silver21.30-0.08
Copper3.67-0.01
Palladium1895.50-11.50
Platinum989.80-7.20
Oil87.77-1.14
Heating Oil3.70-0.07
Natural Gas5.81-0.33

DOWNLOAD FREE REPORTS

×